Unlock instant, AI-driven research and patent intelligence for your innovation.

Immunogenic wt-1 peptides and methods of use thereof

A technology for immune regulation and vaccines, applied in chemical instruments and methods, peptides, specific peptides, etc., can solve the unsatisfied problems of WT1-derived peptides

Active Publication Date: 2019-04-02
MEMORIAL SLOAN KETTERING CANCER CENT
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, there is an unmet need for WT1-derived peptides that could potentially be used in a large part of the world's population

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunogenic wt-1 peptides and methods of use thereof
  • Immunogenic wt-1 peptides and methods of use thereof
  • Immunogenic wt-1 peptides and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0278] Example 1. Materials and methods

[0279] Peptide design. Using three computer-based predictive algorithms BIMAS (http: / / www-bimas.cit.nih.gov / cgi-bin / molbio / ken_parker_combo form), SYFPEITHI (http: / / www.syfpeithi.de / ) and RANKPEP (http: / / bio.dfci.harvard.edu / Tools / rankpep.html), select epitopes against CD8 and CD4 T cells by starting with the native WT1 protein sequence capable of inducing an immune response in normal donors. Metamorphic peptides were designed by changing a single amino acid in the anchor residue of a class I native peptide, which resulted in higher predicted binding than its native sequence. Class II peptides were designed to simultaneously stimulate CD4 and CD8 T cells by adding flanking residues to class I peptides. While many sequences can be predicted by the algorithms, in 30% of cases these models do not predict binding to MHC when tested on hepatocytes (Gomez-Nunez et al., Leuk Res. 2006;30 (10):1293-8), so in vitro testing is necessary. In a...

Embodiment 2

[0286] Example 2. Binding of natural and analog peptides to HLA-A0201 and HLA-A2402

[0287] The use of pools of 15mer overlapping peptides spanning the human WT1 protein to sensitize human T cells in vitro, in the case of HLA-A2402, the sequence 239-248 (NQMNLGATL; SEQ ID NO:5; abbreviated herein as NQM or ) has recently been described. Identified as an immunogenic CD8 T cell epitope (Doubrovina et al., Blood 2012;123(8):1633-46). To generate similar peptides that are more immunogenic, native peptides and those with various amino acid substitutions in positions 2 and 9 (class I anchor residues) were screened using three online available databases (BIMAS, RANKPEP, and SYFPEITHI). Predictive scores for possible analogs. Predicted binding scores from all three databases showed that the native NQMNLGATL (SEQ ID NO:5) peptide bound better to HLA-A0201 than to the HLA-A2402 molecule (Table I). When glutamine at position 2 was replaced by leucine, binding scores to HLA-A2402 remai...

Embodiment 3

[0291] Example 3. Binding of peptides to HLA-A0201 and HLA-A2402 molecules

[0292] Immunogenicity of MHC class I-restricted peptides requires the ability to bind and stabilize MHC class I molecules on the surface of living cells. Furthermore, in silico predictions are only at best 70% accurate; therefore, the interaction between peptides and HLA-A0201 molecules is limited by conventional binding and stabilization assays using antigen transport deficient (TAP2-negative) HLA-A0201 human T2 cells. The strength of seeks a direct measurement. T2 cells lack TAP function and are therefore defective in proper loading of class I molecules with antigenic peptides produced in the cytosol. Association of exogenously added peptides with thermolabile empty HLA-A0201 molecules stabilizes them and leads to increased levels of surface HLA-A0201 that can be recognized by specific anti-HLA-A0201 mAbs such as BB7.2.

[0293] T2 binding assays showed that the native NQMNLGATL (SEQ ID NO:5) pept...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
affinityaaaaaaaaaa
affinityaaaaaaaaaa
Login to View More

Abstract

The present invention provides peptides, immunogenic compositions and vaccines, as well as methods of treating, reducing the incidence of, and inducing an immune response to WT1-expressing cancers, including metamorphosis derived from WT-1 protein peptide.

Description

[0001] governmental support [0002] This application was supported by grant P01 23766 from the National Institutes of Health. The government has rights in this invention. technical field [0003] The present invention provides peptides, compositions and vaccines comprising said peptides, and methods of treating, reducing the incidence of WT1 expressing cancers and inducing an immune response to WT1 expressing cancers comprising administering said peptides , Compositions and vaccines comprising said peptides. Background technique [0004] Wilms tumor (WT), a pediatric Wilms tumor occurring with a frequency of 1 in 10,000 in newborns, has been the subject of intensive clinical and basic research for several years. The tumors are of embryonal origin, are usually detected in children younger than 5 years of age and can occur unilaterally or bilaterally. WT occurs when the condensed mesenchymal cells of the developing kidney fail to differentiate properly. The involvement o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/00A61K39/38C12N15/11
CPCA61K2039/572C07K14/4748A61K2039/5154A61P35/00A61P35/02A61P37/04A61K39/001153Y02A50/30C07K7/06C07K7/08
Inventor D·A·沙因贝格T·道
Owner MEMORIAL SLOAN KETTERING CANCER CENT